Communiqués de presse


Le groupe Zur Rose demande une augmentation de capital

Conformément à la communication du 18 octobre 2018, le groupe Zur Rose reprend les activités e-commerce de medpex, troisième plus grande pharmacie en ligne en Allemagne, dont le siège est à Ludwigshafen. Avec cette transaction, le groupe Zur Rose renforce de manière significative sa position de leader sur le marché allemand de la vente en ligne de médicaments.

Le groupe envisage de financer l’acquisition de medpex ainsi que d’autres initiatives de croissance organique par une augmentation de capital d’environ CHF 200 millions. Le groupe convoque par conséquent une assemblée générale extraordinaire le 19 novembre 2018. Le conseil d'administration demande une augmentation ordinaire du capital pour l’émission d’un maximum de 3 millions de nouvelles actions. Sous réserve d’accord de l’assemblée générale de la proposition du conseil d’administration, l’augmentation ordinaire du capital se fera sous forme d’une offre de souscription.  Les actionnaires actuels de Zur Rose Group AG bénéficieront d’un droit de souscription proportionnel des nouvelles actions à émettre. Les conditions définitives (ratio de souscription ainsi que le nombre maximum des nouvelles actions à émettre) seront communiquées avant l’émission des droits de souscription.

En tant que Coordinateurs Globaux Associés et Teneurs de Livres Associés, Morgan Stanley et UBS garantissent l’émission des droits de souscription.

Contact pour les analystes et investisseurs

Marcel Ziwica, Chief Financial Officer

E-mail: ir@zurrose.com, téléphone: +41 58 810 11 49

Contact pour les médias

Lisa Lüthi, Responsable Communication d’entreprise

E-mail: media@zurrose.com, téléphone: +41 52 724 08 14

Calendrier financier

19 novembre 2018                   Assemblée générale extraordinaire

23 janvier 2019                        Chiffre d’affaires 2018

21 mars 2019                            Résultat annuel 2018

17 avril 2019                             Q1/2019 Trading Update

23 mai 2019                              Assemblée générale

 
Groupe Zur Rose

Le groupe Zur Rose est la plus grande pharmacie de vente par correspondance d’Europe et l’un des plus importants grossistes pour le corps médical en Suisse. Avec son modèle commercial, il offre un approvisionnement pharmaceutique fiable et de qualité au meilleur prix et contribue ainsi à la réduction des dépenses de santé. Il se distingue en outre par sa volonté de développement constant des services numériques dans le domaine de la gestion des médicaments, pour une plus grande sécurité des traitements. La création de valeur ajoutée et l’orientation patient très marquée font du groupe un partenaire stratégique essentiel pour les fournisseurs de prestations, les répondants des coûts et l’industrie.

Le groupe Zur Rose est présent à l’international avec des marques fortes, notamment en Allemagne avec la célèbre marque de pharmacie DocMorris. La société emploie plus de 1000 collaborateurs sur différents sites et a réalisé un chiffre d’affaires de 983 millions de francs durant l’exercice 2017. Les actions de Zur Rose Group AG sont cotées à la SIX Swiss Exchange (n° de valeur 4261528, ISIN CH0042615283, ticker «ROSE»). L’emprunt d’entreprise de plus de 115 millions de francs émis en juillet 2018 est également coté à la SIX Swiss Exchange (n° de valeur 42146044, ISIN CH0421460442, ticker «ZRO18»). Plus d’informations sur zurrosegroup.com.

Disclaimer

This document and the information contained herein are not for distribution in or into (directly or indirectly) the United States, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful. This document does not constitute an offer of securities for sale in or into the United States, Canada, Australia or Japan.

This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The securities of Zur Rose Group AG to which these materials relate have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will not be a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this communication will be made solely to “qualified institutional buyers” as defined in, and in reliance on, Rule 144A under the Securities Act.

This document is not an issuance or listing prospectus or a similar document in the sense of article 652a, article 752 and/or article1156 of the Swiss Code of Obligations or articles 27 et seq. of the Listing Rules of the SIX Swiss Exchange and was not reviewed by any competent authority. Any offer of securities of Zur Rose Group AG will be made solely by means of, and on the basis of, an offering memorandum that will contain detailed information about the group and its management as well as risk factors and financial statements. Any person considering the purchase of any securities of Zur Rose Group AG must inform itself independently based solely on such offering memorandum (including any supplement thereto).

This document does not constitute an "offer of securities to the public" within the meaning of Directive 2003/71/EC of the European Union, as amended (the "Prospectus Directive") of the securities referred to herein in any member state of the European Economic Area (the "EEA"). Any offers of the securities referred to in this document to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities. In any EEA Member State that has implemented the Prospectus Directive, this document is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This communication may contain statements about the future that use words such as, for example, "believe", "assume", "expect" and other similar expressions. Such statements about the future are subject to risks, uncertainties, and other factors, which can cause the true results of the company to differ significantly from that which is expressly or implicitly assumed in these statements. In view of these uncertainties, the reader should not depend on this type of statement about the future. The company gives no undertaking whatever to update such statements regarding the future, or to adapt them to future events or developments.

retour
PDF PDF
Zur Rose Group AG Logo
Zur Rose Group
Zur Rose Group AG Logo Button open menu
Button close menu
Zur Rose Group